• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.

作者信息

Lichtenstein Gary R

机构信息

Professor of Medicine Vice Chief, Division of Gastroenterology Development and Philanthropy Emeritus Director, Center for Inflammatory Bowel Disease The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania University of Pennsylvania Health System Hospital of the University of Pennsylvania Gastroenterology Division, Department of Internal Medicine Perelman Center for Advanced Medicine Philadelphia, Pennsylvania.

出版信息

Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):13-18.

PMID:38445185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910373/
Abstract
摘要

相似文献

1
Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会2023年年度科学会议溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):13-18.
2
Report from the ACG. Highlights from the American College of Gastroenterology. 66th Annual Scientific Meeting. October 19-23, 2001, Las Vegas, NV.美国胃肠病学会报告。美国胃肠病学会亮点。第66届年度科学会议。2001年10月19日至23日，内华达州拉斯维加斯。
Rev Gastroenterol Disord. 2001;1(4):199-205.
3
Highlights in Crohn's Disease From the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会（ACG）2023年年度科学会议克罗恩病亮点：评论
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 8):23-27.
4
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From:: The 76th American College of Gastroenterology Annual Scientific Meeting and Postgraduate CourseOctober 28-November 2, 2011Washington, DCThe 62nd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 4-8, 2011San Francisco, California2011 Advances in Inflammatory Bowel Diseases/Crohn's & Colitis Foundations Clinical and Research ConferenceDecember 1-3, 2011Hollywood, Florida.《胃肠病学与肝病学最新进展综合报告》来源：第76届美国胃肠病学会年度科学会议及研究生课程，2011年10月28日至11月2日，华盛顿特区；美国肝病研究协会第62届年会，2011年11月4日至8日，加利福尼亚州旧金山；2011年炎症性肠病/克罗恩病与结肠炎基金会临床及研究会议，2011年12月1日至3日，佛罗里达州好莱坞。
Gastroenterol Hepatol (N Y). 2012 Mar;8(Spring 2012 Spec. Ed.):1-26.
5
Highlights in Ulcerative Colitis From the ACG Annual Scientific Meeting: Commentary.美国胃肠病学会年会溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):13-16.
6
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版：欧洲克罗恩病和结肠炎组织（ECCO）第14届大会炎症性肠病亮点：对第14届欧洲克罗恩病和结肠炎组织（ECCO）大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY：维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析：维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合：U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性：GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗（PAILOT）随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗：中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性：EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究：疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析 医学教授 胃肠病学和肝病科 梅奥诊所 明尼苏达州罗切斯特
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.
7
Analysis of Speaker Introduction Formality by Gender at the American College of Gastroenterology 2020 Annual Scientific Meeting.美国胃肠病学会2020年年度科学会议上按性别对演讲者介绍的正式程度进行的分析。
Dig Dis Sci. 2022 Apr;67(4):1209-1212. doi: 10.1007/s10620-021-07136-6. Epub 2021 Jul 18.
8
Best of ACG 2006: Highlights From the 71st Annual Scientific Meeting of the American College of Gastroenterology, October 20-25, 2006, Las Vegas, Nevada.2006年美国胃肠病学会最佳成果：2006年10月20日至25日在内华达州拉斯维加斯举行的第71届美国胃肠病学会年度科学会议亮点
Gastroenterol Hepatol (N Y). 2007 Jan;3(1):41-8.
9
Abstracts of the 72nd Annual Scientific Meeting of the American College of Gastroenterology.美国胃肠病学会第72届年度科学会议摘要
Am J Gastroenterol. 2007 Sep;102 Suppl 2:S119-595. doi: 10.1111/j.1572-0241.2007.01491_1.x.
10
Abstracts of the 66th annual scientific meeting of the American College of Gastroenterology. October 22-24, 2001. Las Vegas, Nevada, USA.美国胃肠病学会第66届年度科学会议摘要。2001年10月22日至24日。美国内华达州拉斯维加斯。
Am J Gastroenterol. 2001 Sep;96(9 Suppl):S1-376.

本文引用的文献

1
Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study.中度至重度活动性溃疡性结肠炎患者的瑞莎珠单抗诱导治疗：3期随机INSPIRE研究中的疗效与安全性
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):9-10.
2
Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis.在etrasimod诱导治疗的2天内观察到症状改善：溃疡性结肠炎患者的ELEVATE UC 52和ELEVATE UC 12研究结果。
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):6-7.
3
Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study.古塞库单抗诱导治疗对中度至重度活动性溃疡性结肠炎的早期症状改善：3期QUASAR研究结果
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):2-3.
4
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.乌帕替尼治疗可在诱导治疗的第 1 天就开始减轻溃疡性结肠炎症状。
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2347-2358.e6. doi: 10.1016/j.cgh.2022.11.029. Epub 2022 Dec 1.
5
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.托法替尼治疗溃疡性结肠炎（TOUR）：在真实环境中启动托法替尼治疗后的早期应答。
Inflamm Bowel Dis. 2023 Apr 3;29(4):570-578. doi: 10.1093/ibd/izac121.
6
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.生物制剂和小分子药物治疗中重度溃疡性结肠炎患者的疗效和安全性：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29.
7
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.系统评价和荟萃分析：急性重度溃疡性结肠炎的最佳挽救治疗。
Inflamm Bowel Dis. 2019 Jun 18;25(7):1169-1186. doi: 10.1093/ibd/izy383.
8
Infliximab in ulcerative colitis.英夫利昔单抗治疗溃疡性结肠炎
Biologics. 2008 Sep;2(3):379-88. doi: 10.2147/btt.s2249.